The history of Bioniche Life Sciences began in London, Ontario in 1979. Graeme McRae, Chairman, President & CEO, launched a small animal health products company called Vetrepharm with support from a group of Canadian veterinarians. The vision they shared was to develop innovative medicines and vaccines for animal health that would help to reduce the level of antibiotics commonly used in the livestock industry.
Over the years, Bioniche has evolved into a research-based, technology-driven Canadian biopharmaceutical company that discovers, develops, manufactures, and markets proprietary products for human and animal health markets worldwide. The company now employs approximately 200 people and has three principal reporting divisions: Human Health, Animal Health, and Food Safety. Corporate headquarters are located in Belleville, Ontario, with research, manufacturing, and marketing/sales facilities in Belleville; Montreal, Quebec; Athens, Georgia; Pullman, Washington; and Armidale, Australia.
Bioniche is now poised for a new level of growth, with an expanded global presence, and a portfolio of products and technologies in development that promises to have a profound impact on the converging world of human and animal health. Effective therapies for bladder cancer and potentially other cancers; a cattle vaccine to help prevent E. coli O157:H7 infection; technologies to improve reproduction and potentially replace the use of antibiotics in livestock: these are key areas of strategic focus for Bioniche.